18325-1-AP

antibody from Proteintech Group

Targeting: EGLN3 HIFPH3, PHD3

Provider product page for 18325-1-AP

Western blot

ELISA

Immunoprecipitation

Immunohistochemistry

Antibody data

Antibody Data
Antigen structure
References [17]
Comments [0]
Validations
Western blot [1]
Immunohistochemistry [2]

Submit

Product number: 18325-1-AP - Provider product page
Provider: Proteintech Group
Proper citation: Proteintech Cat#18325-1-AP, RRID:AB_10640673
Product name: PHD3 antibody
Antibody type: Polyclonal
Description: KD/KO validated PHD3 antibody (Cat. #18325-1-AP) is a rabbit polyclonal antibody that shows reactivity with human and has been validated for the following applications: IHC, IP, WB,ELISA.
Reactivity: Human
Host: Rabbit
Conjugate: Unconjugated
Isotype: IgG
Vial size: 20ul, 150ul

EGLN3 protein structure - 18325-1-AP shown in red.

Submitted references HCMV infection depends on EGLN1-mediated mitochondrial activation to increase dNTP pools for viral DNA replication.

Simpson LA, Dunn DM, Fales W, Moore ZJ, Ciesla JH, Waild NC, Raymonda MH, Harris IS, Munger J
Cell reports 2026 Apr 29;45(5):117329

HCMV infection depends on EGLN1-mediated mitochondrial activation to increase dNTP pools for viral DNA replication.

Simpson LA, Dunn DM, Fales W, Moore ZJ, Ciesla JH, Waild N, Raymonda MH, Harris IS, Munger J
bioRxiv : the preprint server for biology 2025 Oct 31;

Pseudohypoxia-Stabilized HIF2α Transcriptionally Inhibits MNRR1, a Druggable Target in MELAS.

Purandare N, Pasupathi V, Xi Y, Rajan V, Vegh C, Firestine S, Kozicz T, Fribley AM, Grossman LI, Aras S
Cells 2025 Jul 15;14(14)

Targeting P4HA1 promotes CD8(+) T cell progenitor expansion toward immune memory and systemic anti-tumor immunity.

Ma S, Ong LT, Jiang Z, Lee WC, Lee PL, Yusuf M, Ditzel HJ, Wang Y, Chen Q, Wang W, Wu X, Tan EY, Yu Q
Cancer cell 2025 Feb 10;43(2):213-231.e9

Trans-resveratrol mitigates miR-204-3p mediated progression of allergic rhinitis by regulating the EGLN3/HIF-1α/IL33/ST2 signalling pathway.

Mao W, Wang B, Chen F, Luo D, Li Y, Liu Y, Liu Y, Dong P, Huang R
Phytomedicine : international journal of phytotherapy and phytopharmacology 2024 Nov;134:155967

Cancer-associated fibroblast-secreted FGF7 as an ovarian cancer progression promoter.

Feng S, Ding B, Dai Z, Yin H, Ding Y, Liu S, Zhang K, Lin H, Xiao Z, Shen Y
Journal of translational medicine 2024 Mar 15;22(1):280

Hypoxia induces mitochondrial protein lactylation to limit oxidative phosphorylation.

Mao Y, Zhang J, Zhou Q, He X, Zheng Z, Wei Y, Zhou K, Lin Y, Yu H, Zhang H, Zhou Y, Lin P, Wu B, Yuan Y, Zhao J, Xu W, Zhao S
Cell research 2024 Jan;34(1):13-30

Dexmedetomidine promotes colorectal cancer progression via Piwil2 signaling.

Dong J, Che J, Wu Y, Deng Y, Jiang X, He Z, Zhang J
Cellular oncology (Dordrecht, Netherlands) 2024 Aug;47(4):1459-1474

CHD1 deletion stabilizes HIF1α to promote angiogenesis and glycolysis in prostate cancer.

Wang YZ, Qian YC, Yang WJ, Ye LH, Guo GD, Lv W, Huan MX, Feng XY, Wang K, Yang Z, Gao Y, Li L, Chen YL
Asian journal of andrology 2023 Mar-Apr;25(2):152-157

E3 ligase MAEA-mediated ubiquitination and degradation of PHD3 promotes glioblastoma progression.

Zhou P, Peng X, Tang S, Zhang K, Tan Z, Li D, Shen L, Peng J, Yang L
Oncogene 2023 Apr;42(16):1308-1320

Ryanodine receptor 2 promotes colorectal cancer metastasis by the ROS/BACH1 axis.

Chen T, Zhang X, Ding X, Feng J, Zhang X, Xie D, Wang X
Molecular oncology 2023 Apr;17(4):695-709

A novel hypoxia-driven gene signature that can predict the prognosis of hepatocellular carcinoma.

Zeng Z, Lei S, Wang J, Yang Y, Lan J, Tian Q, Chen T, Hao X
Bioengineered 2022 May;13(5):12193-12210

Cancer associated fibroblast-derived CCL5 promotes hepatocellular carcinoma metastasis through activating HIF1α/ZEB1 axis.

Xu H, Zhao J, Li J, Zhu Z, Cui Z, Liu R, Lu R, Yao Z, Xu Q
Cell death & disease 2022 May 20;13(5):478

WDR5 facilitates EMT and metastasis of CCA by increasing HIF-1α accumulation in Myc-dependent and independent pathways.

Chen T, Li K, Liu Z, Liu J, Wang Y, Sun R, Li Z, Qiu B, Zhang X, Ren G, Xu Y, Zhang Z
Molecular therapy : the journal of the American Society of Gene Therapy 2021 Jun 2;29(6):2134-2150

Prolyl hydroxylase 3 involvement in lung cancer progression under hypoxic conditions: association with hypoxia-inducible factor-1α and pyruvate kinase M2.

Chu X, Xiang M, Feng L, Liu H, Zhou C
Journal of thoracic disease 2019 Sep;11(9):3941-3950

Prolyl Hydroxylase 3 Attenuates MCL-1-Mediated ATP Production to Suppress the Metastatic Potential of Colorectal Cancer Cells.

Radhakrishnan P, Ruh N, Harnoss JM, Kiss J, Mollenhauer M, Scherr AL, Platzer LK, Schmidt T, Podar K, Opferman JT, Weitz J, Schulze-Bergkamen H, Koehler BC, Ulrich A, Schneider M
Cancer research 2016 Apr 15;76(8):2219-30

Overexpression of the HIF hydroxylase PHD3 is a favorable prognosticator for gastric cancer.

Su C, Huang K, Sun L, Yang D, Zheng H, Gao C, Tong J, Zhang Q
Medical oncology (Northwood, London, England) 2012 Dec;29(4):2710-5

No comments: Submit comment

Supportive validation

Submitted by: Proteintech Group (provider)
Main image
Experimental details: HT-1080 cells were subjected to SDS PAGE followed by western blot with 18325-1-AP(EGLN3 antibody) at dilution of 1:1000
Sample type: cell line

Supportive validation

Submitted by: Proteintech Group (provider)
Main image
Experimental details: Immunohistochemical of paraffin-embedded human brain using 18325-1-AP(EGLN3 antibody) at dilution of 1:50 (under 10x lens)
Sample type: tissue

Supportive validation

Submitted by: Proteintech Group (provider)
Main image
Experimental details: The PHD3 antibody from Proteintech is a rabbit polyclonal antibody to a fusion protein of human PHD3. This antibody recognizes human antigen. The PHD3 antibody has been validated for the following applications: ELISA, WB, IHC analysis.
Appendix: 18325-1-AP.pdf

: Show more